MA49887A - Administration sous-cutanée d'un antagoniste du récepteur p2y12 - Google Patents

Administration sous-cutanée d'un antagoniste du récepteur p2y12

Info

Publication number
MA49887A
MA49887A MA049887A MA49887A MA49887A MA 49887 A MA49887 A MA 49887A MA 049887 A MA049887 A MA 049887A MA 49887 A MA49887 A MA 49887A MA 49887 A MA49887 A MA 49887A
Authority
MA
Morocco
Prior art keywords
receptor antagonist
subcutaneous administration
subcutaneous
administration
antagonist
Prior art date
Application number
MA049887A
Other languages
English (en)
Inventor
Martine Baumann
Markus Kramberg
Markus Rey
Markus Riederer
Sebastien Roux
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of MA49887A publication Critical patent/MA49887A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA049887A 2017-03-15 2018-03-14 Administration sous-cutanée d'un antagoniste du récepteur p2y12 MA49887A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2017056175 2017-03-15

Publications (1)

Publication Number Publication Date
MA49887A true MA49887A (fr) 2020-06-24

Family

ID=61899166

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049887A MA49887A (fr) 2017-03-15 2018-03-14 Administration sous-cutanée d'un antagoniste du récepteur p2y12

Country Status (18)

Country Link
US (1) US11179390B2 (fr)
EP (1) EP3595666A1 (fr)
JP (3) JP7580918B2 (fr)
KR (1) KR102510832B1 (fr)
CN (1) CN110381947A (fr)
AU (1) AU2018234056B2 (fr)
BR (1) BR112019014567A2 (fr)
CL (1) CL2019002318A1 (fr)
EA (1) EA201992123A1 (fr)
IL (1) IL269286B2 (fr)
MA (1) MA49887A (fr)
MX (1) MX393334B (fr)
MY (1) MY205605A (fr)
PH (1) PH12019502111A1 (fr)
SG (1) SG11201908128YA (fr)
TW (1) TWI765002B (fr)
UA (1) UA125531C2 (fr)
WO (1) WO2018167139A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3515924B1 (fr) 2016-09-22 2021-12-15 Idorsia Pharmaceuticals Ltd Formes cristallines
MA49887A (fr) * 2017-03-15 2020-06-24 Idorsia Pharmaceuticals Ltd Administration sous-cutanée d'un antagoniste du récepteur p2y12
SMT202600015T1 (it) 2020-07-15 2026-03-09 Viatris Asia Pacific Pte Ltd Composizione farmaceutica acquosa comprendente un antagonista del recettore p2y12
MX2024000653A (es) 2021-07-13 2024-01-31 Idorsia Pharmaceuticals Ltd Un proceso para la sintesis de ester de butilo de acido 4-((r)-2-{[6-((s)-3-metoxi-pirrolidin-1-il)-2-fenil-pirimidin-4-c arbonil]-amino}-3-fosfono-propionil)-piperazin-1-carboxilico.
US20250197904A1 (en) 2022-03-14 2025-06-19 Viatris Asia Pacific Pte. Ltd. A process for the synthesis of ( r)-2-(( tert-butoxycarbonyl)amino)-3-(diethoxyphosphoryl)propanoic acid or of phosphonate derivatives thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870035A (en) 1970-07-17 1975-03-11 Survival Technology Method and apparatus for self-administering pre-hospital phase treatment of coronary prone individuals in the early minutes or hours after the onset of heart attack symptoms
US4004577A (en) 1972-12-04 1977-01-25 Survival Technology, Inc. Method of treating heart attack patients prior to the establishment of qualified direct contact personal care
JPS5373586A (en) 1976-12-09 1978-06-30 Mitsubishi Chem Ind Ltd New penicillin derivatives
US4795433A (en) 1985-05-20 1989-01-03 Survival Technology, Inc. Automatic injector for emergency treatment
US4658830A (en) 1984-08-08 1987-04-21 Survival Technology, Inc. Method and apparatus for initiating reperfusion treatment by an unattended individual undergoing heart attack symptoms
US5078680A (en) 1984-08-08 1992-01-07 Survival Technology, Inc. Automatic injector for emergency treatment
GR861289B (en) 1985-05-20 1986-09-16 Survival Technology Injection method and apparatus with electrical blood absorbing stimulation
CA2020437A1 (fr) 1989-07-05 1991-01-06 Yoshihide Fuse Derive de cinnamamide
JP2003502314A (ja) 1999-06-14 2003-01-21 イーライ・リリー・アンド・カンパニー 化合物
US6861424B2 (en) 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
DE60333866D1 (de) 2002-12-11 2010-09-30 Bayer Schering Pharma Ag 2-aminocarbonlyl-chinolin-verbindungen als adenosin diphosphat plättchenrezeptor antagonisten
ATE481103T1 (de) 2003-04-09 2010-10-15 Wyeth Llc Derivate von 2-(8,9-dioxo-2,6- diazabicyclo(5.2.0)non-1(7)-en-2- yl)alkylphosphonsäure und deren verwendung als n- methyl-d-aspartat- (nmda-) rezeptorantagonisten
AU2003249865A1 (en) * 2003-06-24 2005-01-21 Actelion Pharmaceuticals Ltd Pyrazolidinedione derivatives and their use as platelet aggregation inhibitors
TW200640877A (en) 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
AU2006305538B2 (en) 2005-10-21 2012-06-28 Idorsia Pharmaceuticals Ltd Piperazine derivatives as antimalarial agents
CL2007002920A1 (es) 2006-10-13 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
CL2007003038A1 (es) 2006-10-25 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.
JP4785881B2 (ja) 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
MX2009011089A (es) 2007-04-23 2009-10-30 Sanofi Aventis Derivados de quinolina-carboxamida en calidad de antagonistas de p2y12.
CA2686203A1 (fr) 2007-05-02 2008-11-13 Portola Pharmaceuticals, Inc. Dosage oral et intraveineux de l'inhibiteur p2y12 reversible et a action directe
EP2225253B1 (fr) 2007-11-29 2012-06-27 Actelion Pharmaceuticals Ltd. Dérivés d'acide phosphonique et leur utilisation en tant qu'antagonistes du récepteur p2y12
EP2238127B1 (fr) 2007-12-26 2012-08-15 Sanofi Dérivés de pyrazole-carboxamide utiles en tant qu'antagonistes de p2y12
EP2238128B1 (fr) 2007-12-26 2012-08-22 Sanofi Pyrazole-carboxamides hétérocycliques utilisés en tant qu'antagonistes du récepteur p2y12
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
MA33260B1 (fr) 2009-04-08 2012-05-02 Actelion Pharmaceuticals Ltd 6-(3-azabicyclo[3.1.0.]hex-3-yl)-2-phenylpyrimidines
CA2756654C (fr) 2009-04-22 2017-08-22 Actelion Pharmaceuticals Ltd Derives de thiazole et leur utilisation comme antagonistes des recepteurs p2y12
WO2011137459A1 (fr) * 2010-04-30 2011-11-03 Portola Pharmaceuticals, Inc. Formes galéniques de l'élinogrel et leurs méthodes d'administration injectables
WO2011160768A1 (fr) 2010-06-23 2011-12-29 Stefan Kralev Dispositif médical permettant une auto-administration par des patients présentant des risques d'accidents coronariens aigus
EP3515924B1 (fr) 2016-09-22 2021-12-15 Idorsia Pharmaceuticals Ltd Formes cristallines
MA49887A (fr) * 2017-03-15 2020-06-24 Idorsia Pharmaceuticals Ltd Administration sous-cutanée d'un antagoniste du récepteur p2y12

Also Published As

Publication number Publication date
AU2018234056A1 (en) 2019-10-31
TW201840323A (zh) 2018-11-16
SG11201908128YA (en) 2019-10-30
EP3595666A1 (fr) 2020-01-22
EA201992123A1 (ru) 2020-02-25
IL269286B1 (en) 2023-04-01
JP2020510043A (ja) 2020-04-02
BR112019014567A2 (pt) 2020-02-18
US11179390B2 (en) 2021-11-23
TWI765002B (zh) 2022-05-21
PH12019502111A1 (en) 2020-03-16
CN110381947A (zh) 2019-10-25
WO2018167139A1 (fr) 2018-09-20
IL269286B2 (en) 2023-08-01
KR102510832B1 (ko) 2023-03-15
US20200129510A1 (en) 2020-04-30
IL269286A (en) 2019-11-28
KR20190124297A (ko) 2019-11-04
CL2019002318A1 (es) 2020-01-10
UA125531C2 (uk) 2022-04-13
JP2023052576A (ja) 2023-04-11
AU2018234056B2 (en) 2023-05-25
MY205605A (en) 2024-10-29
MX393334B (es) 2025-03-24
JP7580918B2 (ja) 2024-11-12
JP2025060907A (ja) 2025-04-10
CA3050831A1 (fr) 2018-09-20
NZ757938A (en) 2024-07-05
MX2019009559A (es) 2019-10-15

Similar Documents

Publication Publication Date Title
IL283134A (en) Alcohol-resistant drug formulations
MA49887A (fr) Administration sous-cutanée d'un antagoniste du récepteur p2y12
HUE059827T2 (hu) VEGF-antagonista alkalmazása angiogén szembetegségek kezelésére
EP3707821A4 (fr) Ensemble plateforme d'ancrage
MA41117A (fr) Imagerie d'un corps
EP3344295A4 (fr) Récepteurs d'antigène chimère tn anti-sialyle
IL271777A (en) Preparations for intravenous administration of medical substances
DK3331886T3 (da) Dopamin-d3-receptorantagonister med en bicyclo-del
EP3658348A4 (fr) Échafaudages imprimés en 3d d'un conjugué peptide-polymère
EP3632898A4 (fr) Antagoniste d'ep4
EP3525841C0 (fr) Micro-dispositif d'administration
EP3345079A4 (fr) Interface combinée glisser-déposer d'un écran de tablette
MA54761A (fr) Administration d'un inhibiteur de signalisation de trans-signalisation par il-6 sélectif
EP3627775A4 (fr) Synchronisation d'itinéraire
EP3334413A4 (fr) Dispositif d'administration
EP3863629A4 (fr) Promédicaments d'antagonistes du cgrp
IL283673A (en) Deuterated analogs of acetyl-leucine
EA201890156A1 (ru) Антагонисты рецептора cgrp
DK3512518T3 (da) Buprenophinformuleringer med langvarig frigivelse
EP3368401A4 (fr) Adaptateur d'ancrage
HUE058114T2 (hu) Cediranib rögzített idõszakos adagolását tartalmazó eljárások
EP3733243A4 (fr) Procédé d'administration de médicament
HUE055083T2 (hu) Tiszta 5-HT6 receptor antagonisztika kombinációja az NMDA receptor antagonistájával
FR3030165B1 (fr) Synchronisation d'un reseau cpl
EP3689870A4 (fr) Médicament analgésique utilisant un médicament antagoniste du récepteur pac1